Provision Breakdown

  • 21 CFR 1306.7(b)
  • This regulation is commonly known as the “three-day rule.”
  • The provision permits the use of buprenorphine to relieve acute symptoms of withdrawal so that treatment arrangements may be made for a patient by physicians who do not possess the waiver normally required by federal law and issued by the Drug Enforcement Administration for buprenorphine prescribing and treatment.
  • A physician administering buprenorphine through this regulation may only administer one day’s worth of medication at a time, for a maximum of three days.
Disclaimer: This website is to be used for educational purposes only. The information on this site is not intended to provide legal advice.